Savara Inc banner

Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 5.14 USD -2.65% Market Closed
Market Cap: $1.1B

During the last 3 months Savara Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Dec 19, 2025 by Ramsay David A , who sold 121.2k USD worth of SVRA shares.

Last Transactions:
Ramsay David A
$-121.2k
Hawkins Richard J
$+98.6k
Mccracken Joseph S
$+20.8k
Ramsay David A
$+416.3k
Pauls Matthew
$-180.8k
Hawkins Richard J
$-26.6k
Lowrance David L
$-83.3k
Mccracken Joseph S
$+59.1k
Ramsay David A
$+287.6k
Lowrance David L
$-47.1k
Elam Nevan C
$-442.3k
Pauls Matthew
$-395.9k
Yang Rick
$+1 000k
Growth Equity Opportunities 17, Llc
$+1 000k
Baskett Forest
$+1 000k
Behbahani Ali
$+1 000k
Chang Carmen
$+1 000k
Florence Anthony A. Jr.
$+1 000k
Makhzoumi Mohamad
$+1 000k
Mathers Edward T
$+1 000k
Sandell Scott D
$+1 000k
Walker Paul Edward
$+1 000k
Pratt Raymond Dennis
$+19k
Ramsay David A
$+97.6k
Ramsay David A
$+33.1k
Ramsay David A
$+127.8k
Ramsay David A
$+44.8k
Ramsay David A
$+10.8k
Ramsay David A
$+4.9k
Ramsay David A
$+22.7k
Pratt Raymond Dennis
$+5.4k
Ramsay David A
$+61.1k
View All Transactions

During the last 3 months Savara Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Dec 19, 2025 by Ramsay David A , who sold 121.2k USD worth of SVRA shares.

Sold
0-3
months
0 USD
0
3-6
months
121.2k USD
1
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
2
119.4k USD

Savara Inc
Insider Trading Chart

Savara Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Savara Inc
Last Insider Transactions

Global
Insiders Monitor

Savara Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
1.77 USD
Overvaluation 66%
Intrinsic Value
Price $5.14

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett